Detalles de la búsqueda
1.
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(6): 786-795, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386568
2.
Acceptability of automatic referrals to supportive and palliative care by patients living with advanced lung cancer: qualitative interviews and a co-design process.
Res Involv Engagem
; 10(1): 36, 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38566198
3.
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
JAMA Netw Open
; 7(1): e2352302, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236598
4.
Facts and Hopes: Immunocytokines for Cancer Immunotherapy.
Clin Cancer Res
; 29(19): 3841-3849, 2023 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37227449
5.
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC.
JTO Clin Res Rep
; 4(3): 100460, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36915629
6.
Scoping review protocol on the impact of antimicrobial resistance on cancer management and outcomes.
BMJ Open
; 13(2): e068122, 2023 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36746540
7.
Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Target Oncol
; 18(5): 697-705, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37656263
8.
Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study.
Curr Oncol
; 30(12): 10396-10407, 2023 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38132391
9.
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep
; 4(4): 100482, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37090101
10.
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
Clin Lung Cancer
; 24(3): e152-e159, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36774234
11.
Evolution of an invasive ductal carcinoma to a small cell carcinoma of the breast: A case report.
Medicine (Baltimore)
; 101(2): e28433, 2022 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35029184
12.
Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.
Curr Oncol
; 29(3): 1967-1982, 2022 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35323360
13.
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
JAMA Netw Open
; 5(12): e2245596, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36480204
14.
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers.
Curr Oncol
; 29(10): 7198-7208, 2022 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36290844
15.
A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.
JTO Clin Res Rep
; 2(12): 100249, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34877555
16.
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
Cancer Med
; 10(8): 2618-2626, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724676
17.
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.
Curr Oncol
; 28(5): 4213-4222, 2021 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34677275
18.
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Eur J Cancer
; 151: 115-125, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33975059
19.
Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib.
J Thorac Oncol
; 14(9): 1547-1555, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31108247
20.
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.
Cancers (Basel)
; 11(11)2019 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31684111